Back to search results

Observational Study of Neurodegenerative and Related Disorders

This observational study aims to better understand neurodegenerative disorders like PSP, CBD, PCA, LPA, and Semantic Dementia. Researchers will evaluate participants who have symptoms suggesting one of these conditions. The study uses special PET scans with C-11 PiB to look for amyloid protein, AV1451 Tau to look for tau protein, and C-11 ER176 to look for neuroinflammation (brain inflammation). The main goal is to analyze these imaging results after one year. You may be able to join if you are over 21 and have symptoms of a neurodegenerative disorder. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll 500 participants. It is not a treatment study, but rather aims to learn more about these conditions.
What's involved
You may have a baseline visit and possible yearly follow-up evaluations. These visits could include neurological, speech/language, and neuropsychometric assessments, an MRI, FDG PET/CT, and/or PET scans with C-11 PiB, AV1451 Tau, or C-11 ER176. You will also be asked to provide a blood sample.
Compensation
Not stated in the trial record.
Follow-up
Imaging analysis will be measured at 1 year, and participants could be evaluated on a yearly basis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04680130

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Enrolling by Invitation
Not specifiedAges 21+Observational
Mayo Clinic
~500 participants
Updated 2025-11-21 on ClinicalTrials.gov
What's tested:C-11 PiBAV1451 TauC-11 ER176

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Imaging analysis
Measured over 1 year

Conditions

PSP
CBD
PCA
LPA
Semantic Dementia
Semantic Aphasia
Behavioral Variant of Frontotemporal Dementia
FTD
PPA
Apraxia of Speech
MSA - Multiple System Atrophy
Parkinson Disease

Explore related trials

Apraxic aphoniaBehavioral variant of frontotemporal dementiaCorticobasal DegenerationDegenerative Disease of Nervous System, UnspecifiedFrontotemporal DementiaLogopenic progressive aphasiaMultiple System AtrophyParkinson DiseasePosterior cortical atrophy syndromePrimary Progressive AphasiaProgressive Supranuclear PalsySemantic aphasiaSemantic dementia

Where it's being run

1 sites across 1 states
Minnesota1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All participants will be over the age of 21
Have symptoms suggestive of a neurodegenerative and/or related disorder

Exclusion

Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes
Women that are pregnant or post-partum and breast-feeding will be excluded
Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome
Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts)
Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)

What this trial measures

  • Imaging analysis1 year

    Longitudinal images and correlates will be measured and tracked to determine direct correlations in the brain with disease progression on a yearly basis